William Patterson
Internal Medicine · Birmingham, ALNPI 1245346774
Payments from drug & device makers
Across 225 payments — averaging $14.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$465
- Johnson & Johnson$359
- Boehringer Ingelheim$286
- AstraZeneca$270
- Pfizer$239
- Amarin Pharma, Inc.$198
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,284100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 29 | $465 |
| Johnson & Johnson | 25 | $359 |
| Boehringer Ingelheim | 19 | $286 |
| AstraZeneca | 20 | $270 |
| Pfizer | 17 | $239 |
| Amarin Pharma, Inc. | 15 | $198 |
| AbbVie | 18 | $170 |
| Novartis | 8 | $170 |
| Sanofi-aventis U.S. LLC | 9 | $147 |
| Lilly USA, LLC | 10 | $132 |
| Astellas Pharma US Inc | 9 | $122 |
| Novo Nordisk | 6 | $102 |
| Merck | 6 | $89 |
| Eisai Inc. | 5 | $83 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $65 |
| Kowa Pharmaceuticals America, Inc. | 5 | $64 |
| Esperion Therapeutics, Inc. | 4 | $58 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $49 |
| GSK | 3 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Radius Health, Inc. | 2 | $27 |
| Aytu Biopharma, Inc. | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Antares Pharma, Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
How this compares
$3,289 in reported general payments places this provider in the 75th percentile of 1,533 internal medicine providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $5,228 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $239 | $5,22811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Birmingham
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- William KirbyBirmingham$2.3M
- Jordan VaughnBirmingham$1.6M
- Stefanie KrickBirmingham$527K
- Ryan WeldonBirmingham$458K
- Ashraf KhanBirmingham$215K
- Robert LewisBirmingham$201K
- David WynneBirmingham$180K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.